Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Navidea Biopharmaceuticals Inc    NAVB

Delayed Quote. Delayed  - 07/27 10:02:01 pm
0.5402 USD   +2.66%
07/19 NAVIDEA BIOPHAR : Receives IRB Approval for its Lymphoseek® Rheumato..
06/16 NAVIDEA BIOPHAR : Announces Presentation of Results Demonstrating Pe..
06/14 NAVIDEA BIOPHAR : to Provide Shareholder Update
 SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
07/21/2016 07/22/2016 07/25/2016 07/26/2016 07/27/2016 Date
0.5211(c) 0.5231(c) 0.5182(c) 0.5262(c) 0.5402(c) Last
700 933 324 567 243 885 158 486 518 272 Volume
-5.48% +0.38% -0.94% +1.54% +2.66% Change
More quotes
Financials ($)
Sales 2016 24,7 M
EBIT 2016 -4,56 M
Net income 2016 -12,5 M
Debt 2016 -
Yield 2016 -
Sales 2017 35,9 M
EBIT 2017 4,69 M
Net income 2017 -4,41 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 3,31x
Capi. / Sales2017 2,28x
Capitalization 81,9 M
More Financials
Company
Navidea Biopharmaceuticals, Inc. develops and commercializes precision diagnostics and radiopharmaceutical agents, which are intended to improve diagnostic accuracy, clinical decision-making and patient care.Its current radiopharmaceutical development programs include Lymphoseek, AZD4694 and... 
More about the company
Latest news on NAVIDEA BIOPHARMACEUTICALS
07/19 NAVIDEA BIOPHARMACEUTICALS : Receives IRB Approval for its Lymphoseek® Rheumatoi..
07/18 NAVIDEA BIOPHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K)
06/29 NAVIDEA BIOPHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibi..
06/23 NAVIDEA BIOPHARMACEUTICALS : Announces Presentation of Results Demonstrating Per..
06/16 NAVIDEA BIOPHARMACEUTICALS : Announces Presentation of Results Demonstrating Per..
06/14 NAVIDEA BIOPHARMACEUTICALS : to Provide Shareholder Update
06/02 NAVIDEA BIOPHARMACEUTICALS, INC. : Triggering Events That Accelerate or Increase..
06/02 NAVIDEA BIOPHARMACEUTICALS : Provides Financing Update
06/02 NAVIDEA BIOPHARMACEUTICALS : Announces Data Presentations at 2016 Annual Meeting..
05/26 NAVIDEA BIOPHARMACEUTICALS : $1.8 Million Fast-Track NIH SBIR Grant for Manocept..
More news
Sector news : Biotechnology & Medical Research - NEC
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised -- Update
07/27DJAmgen Profit Rises 13%, 2016 Outlook Raised
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J deal
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
06/14 Navidea to update investors tomorrow on CRG litigation
05/24 Financier says Navidea in default on loan, tries to seize company's accounts
05/17 Navidea Biopharmaceuticals' (NAVB) Management on Q1 2016 Results - Earnings C..
05/17 Navidea Biopharma revenues up 124% in Q1
05/17 Navidea Biopharm beats by $0.01, beats on revenue
Advertisement
Chart NAVIDEA BIOPHARMACEUTICALS
Duration : Period :
Navidea Biopharmaceuticals Technical Analysis Chart | NAVB | US63937X1037 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus
Number of Analysts 1
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mike M. Goldberg Chairman
Jed Andrew Latkin Chief Operating Officer
Frederick O. Cope Chief Scientific Officer & Senior Vice President
Michael Tomblyn Chief Medical Officer & Senior Vice President
David Colborn Vice President-Clinical Operations
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NAVIDEA BIOPHARMACEUTI..-60.44%82
INCYTE CORPORATION-18.19%16 315
CELLTRION, INC.--.--%10 696
LONZA GROUP AG11.40%9 743
QUINTILES TRANSNATIONA..9.23%9 029
ALKERMES PLC-35.74%7 711
More Results